Pembrolizumab and Campylobacter Jejuni Induced Guillain-Barré Syndrome in a Patient with Advanced Duodenal Adenocarcinoma: A Case Report and Literature Review

Abstract

Neurological Immune Related Adverse Events (irAEs) secondary to Immune Checkpoint Inhibitors (ICI) are unncommon with an incidence of 1% to 5%. Among them, the Guillain Barré syndrome may be life-threatening and must be diagnosed early. We describe a clinical case of Guillain Barré Syndrom with a concomitant Campylobacter Jejuni colitis occurring after the first intravenous injection of pembrolizumab. A review of literature regarding the Guillain Barré syndrome after ICI use is added as a complementary source.